To the full analysis
Buyback calculator for Arcutis Biotherapeutics
Arcutis Biotherapeutics stock: key metrics
ARQTArcutis Biotherapeutics had an operating margin of −3.3% and a return on invested capital (ROIC) of −15.7% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2017 | no data | no data | no data |
| 2018 | no data | no data | no data |
| 2019 | no data | no data | no data |
| 2020 | no data | no data | no data |
| 2021 | no data | no data | no data |
| 2022 | 79.5% | −8,183.0% | −8,449.8% |
| 2023 | 91.6% | −404.5% | −439.8% |
| 2024 | 90.3% | −65.3% | −71.3% |
| 2025 | 90.2% | −3.3% | −4.3% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2017 | 99.7% | no data | −100.0% |
| 2018 | 80.3% | −60.5% | −37.7% |
| 2019 | −41.4% | −45.4% | −39.2% |
| 2020 | −50.1% | −57.2% | −45.5% |
| 2021 | −69.3% | −50.1% | −50.6% |
| 2022 | −100.0% | −60.6% | −69.3% |
| 2023 | −100.0% | −53.9% | −76.8% |
| 2024 | −88.9% | −36.1% | −40.1% |
| 2025 | −8.5% | −15.7% | −3.7% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.